The short version of half-life fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-03 and is reviewed periodically as new material appears.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | 31 amino acid residues |
| Molecular formula | C187H291N45O59 | free peptide, no counter-ion |
| Approximate mass | 4114 Da | matches theoretical value |
| Receptor target | Glucagon-like peptide-1 receptor | Gs-coupled, cyclic AMP pathway |
| Circulation half-life | About one week in humans | extended by albumin association |
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
=== Mumps === Mumps is another viral disease that was once very common, especially during childhood. If mumps is acquired by a male who is past puberty, a possible complication is bilateral orchitis, which can in some cases lead to sterility.
== Regulation == In Arabidopsis, two chains of catalytic ALS (InterPro: IPR012846) is complexed with two regulatory small subunits (InterPro: IPR004789), AHASS2 and AHASS1. Such an arrangement is widespread in both bacterial and eukaryotic ALS. The hetromeric structure was demonstrated in E. coli in 1984 and in eukaryotes (S. cerevisiae and Porphyra purpurea) in 1997. Most of the regulatory proteins have an ACT domain (InterPro: IPR002912) and some of them have a NiKR-like C-terminal (InterPro: IPR027271) In bacteria (E. coli)), Acetolactate synthase consists of three pairs of isoforms. Each pair includes a large subunit, which is thought to be responsible for catalysis, and a small subunit for feedback inhibition. Each subunit pair, or ALS I, II, and III respectively, is located on its own operon, ilvBN, ilvGM, and ilvIH (where ilvN regulated ilvB, and vice versa). Together, these operons code for several enzymes involved in branched-chain amino acid biosynthesis. Regulation is different for each operon.
is electron mobility E is the electric field across the depletion region Dn is the diffusion coefficient for electrons Gn is the rate of generation of electrons Rn is the rate of recombination of electrons Similarly, for holes:
Sources: en.wikipedia.org
Sachets, canisters, pads, cards, and emitters Labels and printed indicators Bottle caps and closures Polymer films and multilayer laminates Paper, board, plastic, glass, and metal coatings Trays and moulded package components Adhesives and absorbent structures Electronic tags, sensors, and data loggers The active component may be positioned inside a package without directly touching the product. It may also be immobilised on a food-contact surface or incorporated into the packaging material. System design must consider the quantity of active material, release or absorption rate, package volume, barrier performance, product composition, storage temperature, expected shelf life, migration limits, consumer safety, manufacturing conditions, recycling, and disposal. Edible films, bio-based polymers, biodegradable materials, nanoparticles, natural antimicrobials, and responsive colour indicators are continuing areas of research. Silver nanoparticles and other antimicrobial nanomaterials have been studied for packaging applications, but their migration, toxicity, regulatory status, recycling impact, and environmental effects require evaluation.
Each meal provides about 1,200 kilocalories (5,000 kJ). They are intended to be eaten for a maximum of 21 days (the assumption is that logistics units can provide fresh food rations by then), and have a minimum shelf life of three years (depending on storage conditions). Packaging requirements are strict. MREs must be able to withstand parachute drops from 380 metres (1,250 ft), and non-parachute drops of 30 metres (98 ft). The packaging is required to maintain a minimum shelf life of three and a half years at 27 °C (81 °F), nine months at 38 °C (100 °F), and short durations from −51 °C (−60 °F) to 49 °C (120 °F) must be sustainable. New forms of packaging are being considered to better meet these requirements including the use of zein to replace the foil, which can be easily punctured, conducts heat, and is reflective (which may give away a servicemember's position). Each MRE weighs 510 to 740 grams (18 to 26 oz), depending on the menu. Since MREs contain water in the food, they weigh more than freeze-dried meals providing equivalent calories.
===== MeSH D08.811.277.087 – amidohydrolases ===== MeSH D08.811.277.087.030 – N-acetylmuramoyl-L-alanine amidase MeSH D08.811.277.087.060 – allophanate hydrolase MeSH D08.811.277.087.100 – arylformamidase MeSH D08.811.277.087.116 – asparaginase MeSH D08.811.277.087.125 – aspartylglucosylaminase MeSH D08.811.277.087.180 – beta-lactamases MeSH D08.811.277.087.180.229 – cephalosporinase MeSH D08.811.277.087.180.697 – penicillinase MeSH D08.811.277.087.200 – biotinidase MeSH D08.811.277.087.280 – dihydroorotase MeSH D08.811.277.087.483 – glutaminase MeSH D08.811.277.087.520 – histone deacetylases MeSH D08.811.277.087.610 – nicotinamidase MeSH D08.811.277.087.690 – penicillin amidase MeSH D08.811.277.087.725 – peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase MeSH D08.811.277.087.760 – pyroglutamate hydrolase MeSH D08.811.277.087.831 – sirtuins MeSH D08.811.277.087.902 – urease
Biomedical Sciences Molecular and Cellular Biology Bioengineering and Devices Biophysics, Biochemistry and Structural Biology Climate science, Agriculture and Environment Biotechnology Regulatory Affairs, IPR and Policy
Sources: en.wikipedia.org
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.
The substitution at position 8 removes the site recognised by dipeptidyl peptidase-4, the enzyme that destroys the native hormone within minutes. The linked lipophilic chain then binds circulating albumin, which further limits access by degradative enzymes and reduces renal loss. Together these features lengthen the effective circulation time considerably.
It acts at the glucagon-like peptide-1 receptor, a G protein-coupled receptor that signals mainly through cyclic AMP. Activation is glucose dependent, meaning insulin release is stimulated more strongly when blood glucose is already elevated. Other tissues carrying the same receptor respond as well, which explains effects beyond glucose control.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.